백신 위탁생산 시장 규모, 점유율, 성장 분석 : 개발 단계별, 용도별, 워크플로우별, 백신 종류별, 유형별, 제품 유형별, 최종사용자별, 서비스 유형별, 지역별 - 업계 예측(2025-2032년)

Global Vaccine Contract Manufacturing Market size was valued at USD 2.8 billion in 2023 and is poised to grow from USD 3.04 billion in 2024 to USD 5.83 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).

The global vaccine contract manufacturing market is being significantly propelled by the worldwide expansion of vaccination initiatives, advancements in innovative vaccine technologies, and a strong focus on pandemic preparedness, coupled with increasing investments in research and development. The rising demand for contract manufacturing is particularly prominent in low- and middle-income countries launching new immunization programs. Innovative vaccine platforms, such as mRNA, viral vectors, and recombinant proteins, are set to enhance market growth. Policy commitments and funding from governments and health organizations aim to strengthen manufacturing capabilities for crisis resilience. However, challenges remain, including high infrastructure costs, stringent regulations, shortages of skilled labor, and vulnerabilities within the supply chain that could hinder market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccine Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccine Contract Manufacturing Market Segments Analysis

Global Vaccine Contract Manufacturing Market is segmented by Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type and region. Based on Phase, the market is segmented into Preclinical, Clinical and Commercial. Based on Application, the market is segmented into Human Use and Veterinary. Based on Workflow, the market is segmented into Downstream, Upstream and Others. Based on Vaccine Type, the market is segmented into Attenuated, Inactivated, Subunit-based, Toxoid-based and DNA-based. Based on Type, the market is segmented into Viral, Bacterial and Others. Based on Product Type, the market is segmented into Single Vaccines and Combination Vaccines. Based on End User, the market is segmented into Biopharmaceutical Companies and Research Academies & Government Institutes. Based on Service Type, the market is segmented into Fill-Finish and Bulk Products. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vaccine Contract Manufacturing Market

A key market driver for the Global Vaccine Contract Manufacturing Market is the increasing demand for rapid vaccine development and production capabilities, spurred by public health crises such as pandemics and emerging infectious diseases. As governments and organizations prioritize vaccine accessibility and speed, the need for efficient contract manufacturing services has surged. The collaboration between biotechnology companies and contract manufacturers enables scalability and flexibility, allowing for the swift adaptation to changing health threats. This trend is further amplified by advancements in biomanufacturing technologies, enhancing production capacities and streamlining processes, thus driving significant growth in the contract manufacturing sector.

Restraints in the Global Vaccine Contract Manufacturing Market

One of the key market restraints for the global vaccine contract manufacturing market is the stringent regulatory framework governing vaccine production. Manufacturers must adhere to rigorous quality control standards and regulatory compliance imposed by health authorities, which can lead to increased operational costs and elongated timelines for product development and approval. This can deter smaller companies from entering the market due to the high capital required for compliance, limiting the overall growth potential. Additionally, variable regulatory requirements across different regions may complicate manufacturing processes, creating further challenges for contract manufacturers in meeting diverse market demands efficiently.

Market Trends of the Global Vaccine Contract Manufacturing Market

The Global Vaccine Contract Manufacturing market is witnessing a significant shift towards modular and flexible manufacturing facilities, reflecting the industry's need for agility and scalability. Providers are increasingly adopting modular cleanrooms, prefabricated units, and single-use bioreactors, enabling them to respond swiftly to market fluctuations and support multi-product manufacturing. This trend not only enhances operational efficiency but also allows companies to swiftly pivot their production capabilities in response to emerging demands or new vaccine formulations. As a result, the focus on adaptable manufacturing solutions is set to play a crucial role in shaping the future of vaccine production and supply chain resilience.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Vaccine Contract Manufacturing Market Size by Phase & CAGR (2025-2032)

• Market Overview
• Preclinical
• Clinical
• Commercial

Global Vaccine Contract Manufacturing Market Size by Application & CAGR (2025-2032)

• Market Overview
• Human Use
• Veterinary

Global Vaccine Contract Manufacturing Market Size by Workflow & CAGR (2025-2032)

• Market Overview
• Downstream
• Upstream
• Others

Global Vaccine Contract Manufacturing Market Size by Vaccine Type & CAGR (2025-2032)

• Market Overview
• Attenuated
• Inactivated
• Subunit-based
• Toxoid-based
• DNA-based

Global Vaccine Contract Manufacturing Market Size by Type & CAGR (2025-2032)

• Market Overview
• Viral
• Bacterial
• Others

Global Vaccine Contract Manufacturing Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Single Vaccines
• Combination Vaccines

Global Vaccine Contract Manufacturing Market Size by End User & CAGR (2025-2032)

• Market Overview
• Biopharmaceutical Companies
• Research Academies & Government Institutes

Global Vaccine Contract Manufacturing Market Size by Service Type & CAGR (2025-2032)

• Market Overview
• Fill-Finish
• Bulk Products

Global Vaccine Contract Manufacturing Market Size & CAGR (2025-2032)

• North America (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
  • US
  • Canada
• Europe (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Phase, Application, Workflow, Vaccine Type, Type, Product Type, End User, Service Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Diosynth Biotechnologies (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDT Biologika GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim BioXcellence (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CordenPharma (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KBI Biopharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siegfried Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novasep (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Richter-Helm BioLogics GmbH & Co. KG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syngene International Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations